New triple therapy aims to shrink stomach tumors before surgery
NCT ID NCT06766578
First seen May 03, 2026 · Last updated May 25, 2026 · Updated 8 times
Summary
This study tests a new approach for people with locally advanced stomach or gastroesophageal junction cancer. Before surgery, patients receive a combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX). The goal is to see if this treatment can completely eliminate the cancer before surgery. The study involves 32 participants and is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Provincial Hospital
RECRUITINGJinan, Shandong, 250021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.